SG11202102104SA - Dengue vaccine unit dose and administration thereof - Google Patents
Dengue vaccine unit dose and administration thereofInfo
- Publication number
- SG11202102104SA SG11202102104SA SG11202102104SA SG11202102104SA SG11202102104SA SG 11202102104S A SG11202102104S A SG 11202102104SA SG 11202102104S A SG11202102104S A SG 11202102104SA SG 11202102104S A SG11202102104S A SG 11202102104SA SG 11202102104S A SG11202102104S A SG 11202102104SA
- Authority
- SG
- Singapore
- Prior art keywords
- administration
- unit dose
- dengue vaccine
- vaccine unit
- dengue
- Prior art date
Links
- 208000001490 Dengue Diseases 0.000 title 1
- 206010012310 Dengue fever Diseases 0.000 title 1
- 208000025729 dengue disease Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18192711 | 2018-09-05 | ||
| EP18192717 | 2018-09-05 | ||
| EP18192701 | 2018-09-05 | ||
| EP18192787 | 2018-09-05 | ||
| EP18192793 | 2018-09-05 | ||
| EP18192800 | 2018-09-05 | ||
| EP18192776 | 2018-09-05 | ||
| EP18192814 | 2018-09-05 | ||
| EP19154334 | 2019-01-29 | ||
| EP19161184 | 2019-03-07 | ||
| US16/295,611 US11464815B2 (en) | 2018-09-05 | 2019-03-07 | Dengue vaccine unit dose and administration thereof |
| PCT/US2019/049749 WO2020051334A1 (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102104SA true SG11202102104SA (en) | 2021-04-29 |
Family
ID=69722836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102104SA SG11202102104SA (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20220226401A1 (en) |
| EP (3) | EP3846849A1 (en) |
| JP (1) | JP2024105238A (en) |
| KR (1) | KR20210071979A (en) |
| CN (1) | CN112912106A (en) |
| AU (1) | AU2019335006B2 (en) |
| BR (1) | BR112021003962A2 (en) |
| CA (1) | CA3111332A1 (en) |
| CO (1) | CO2021003931A2 (en) |
| DK (1) | DK3620174T3 (en) |
| EC (1) | ECSP21023398A (en) |
| ES (1) | ES2908304T3 (en) |
| IL (2) | IL298307A (en) |
| MX (1) | MX2021002586A (en) |
| PE (1) | PE20211545A1 (en) |
| PH (1) | PH12021550479A1 (en) |
| SG (1) | SG11202102104SA (en) |
| WO (1) | WO2020051334A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11007261B2 (en) * | 2016-04-13 | 2021-05-18 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| CN112912106A (en) * | 2018-09-05 | 2021-06-04 | 武田疫苗股份有限公司 | Dengue vaccine unit dose and administration thereof |
| WO2021174059A1 (en) * | 2020-02-27 | 2021-09-02 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| CN112813089A (en) * | 2021-03-22 | 2021-05-18 | 苏州诺威百奥生物科技有限公司 | Preparation method of multi-site recombinant antigen for flaviviridae detection |
| CN113913551B (en) * | 2021-06-22 | 2022-05-13 | 中国检验检疫科学研究院 | Sequencing primer, detection method and kit for dengue virus typing |
| WO2024086605A1 (en) | 2022-10-18 | 2024-04-25 | Takeda Vaccines, Inc. | Dengue vaccine formulation |
| WO2024086681A1 (en) * | 2022-10-20 | 2024-04-25 | Takeda Vaccines, Inc. | A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype |
| EP4375381A1 (en) * | 2022-11-18 | 2024-05-29 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810092A (en) | 1986-02-21 | 1989-03-07 | Midac Corporation | Economical spectrometer unit having simplified structure |
| JPH084508B2 (en) | 1987-09-16 | 1996-01-24 | 国立予防衛生研究所長 | Recombinant vaccinia virus |
| JP2511494B2 (en) | 1988-05-12 | 1996-06-26 | 善治 松浦 | Method for producing Japanese encephalitis virus surface antigen protein |
| US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| IL91304A0 (en) | 1988-08-20 | 1990-03-19 | Us Health | Recombinant vaccinia virus for prevention of disease caused by flavivirus |
| US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5494671A (en) | 1990-08-27 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | C-terminally truncated dengue and Japanese encephalitis virus envelope proteins |
| EP0872553B1 (en) | 1991-09-19 | 2000-11-15 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES | Chimeric and/or growth-restricted flaviviruses |
| JPH05276941A (en) | 1992-02-28 | 1993-10-26 | Nippon Zeon Co Ltd | Production of noninfectious structure particle containing surface antigen protein of virus belonging to family flavivirus |
| DE69624815T2 (en) | 1995-05-24 | 2003-07-10 | Hawaii Biotech Group | UNIT UNIT VACCINE AGAINST FLAVIVIRUS INFECTION |
| AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| ES2244050T3 (en) | 1997-02-28 | 2005-12-01 | Acambis Inc. | FLAVIVIRUS CHEMICAL VACCINES. |
| DE69833002T2 (en) | 1997-10-08 | 2006-08-24 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | CHIMERIC VACCINE AGAINST THE TARGET CERPHALITIS VIRUS |
| BR9910830A (en) | 1998-06-04 | 2001-02-13 | Us Gov Health & Human Serv | Nucleic acid vaccines to prevent flavivirus infection |
| ES2374131T3 (en) | 2000-02-16 | 2012-02-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | AVIRULENT AND IMMUNOGEN CHIMERIC FLAVIVIRUS. |
| EP1372711A4 (en) | 2001-03-12 | 2005-06-01 | Univ Yale | Compositions and methods comprising west nile virus polypeptides |
| WO2003101397A2 (en) | 2002-05-31 | 2003-12-11 | Acambis, Inc. | Tetravalent dengue vaccines |
| JP5075120B2 (en) | 2005-06-17 | 2012-11-14 | サノフィ・パスツール | Dengue fever cello type 2 attenuated strain |
| EP1924280A4 (en) | 2005-08-10 | 2008-12-10 | Acambis Inc | Vaccination against dengue virus infection |
| FR2903605A1 (en) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE |
| FR2906724B1 (en) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE. |
| FR2909286B1 (en) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE |
| DK2178903T3 (en) | 2007-07-13 | 2012-06-18 | Florida Gulf Coast University | Optimized dengue virus access inhibited peptide (DN81) |
| SG157244A1 (en) | 2008-05-15 | 2009-12-29 | Mp Biomedicals Asia Pacific Pte Ltd | Point of care test for the detection of exposure or immunity to dengue virus |
| WO2010085358A2 (en) | 2009-01-23 | 2010-07-29 | The Board Of Regents Of The University Of Texas System | Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof |
| NZ597000A (en) | 2009-06-01 | 2014-07-25 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| BRPI0904020B8 (en) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | vaccine composition against the dengue virus, and kit |
| EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
| CA2915027A1 (en) | 2012-06-10 | 2013-12-19 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
| EP2877208B1 (en) | 2012-07-24 | 2021-05-12 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
| JP2015524422A (en) | 2012-07-24 | 2015-08-24 | サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ | Vaccine composition |
| TW201920677A (en) | 2012-11-08 | 2019-06-01 | 美商武田疫苗股份有限公司 | Compositions, methods and uses for dengue virus serotype-4 constructs |
| WO2014093182A1 (en) * | 2012-12-14 | 2014-06-19 | Inviragen, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
| KR20240014580A (en) | 2013-03-15 | 2024-02-01 | 다케다 백신즈 인코포레이티드 | Compositions and methods for dengue virus chimeric constructs in vaccines |
| CN106999564A (en) | 2014-09-02 | 2017-08-01 | 赛诺菲巴斯德有限公司 | For the vaccine combination of dengue fever virus disease |
| WO2017005654A1 (en) | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination. |
| BR112017028212A2 (en) | 2015-07-03 | 2018-09-11 | Sanofi Pasteur | concomitant vaccination against dengue and yellow fever |
| US10004795B2 (en) | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
| US11007261B2 (en) * | 2016-04-13 | 2021-05-18 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| CN112912106A (en) * | 2018-09-05 | 2021-06-04 | 武田疫苗股份有限公司 | Dengue vaccine unit dose and administration thereof |
| US11464815B2 (en) * | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
-
2019
- 2019-09-05 CN CN201980070866.0A patent/CN112912106A/en active Pending
- 2019-09-05 PE PE2021000288A patent/PE20211545A1/en unknown
- 2019-09-05 DK DK19195692.9T patent/DK3620174T3/en active
- 2019-09-05 EP EP19769699.0A patent/EP3846849A1/en active Pending
- 2019-09-05 IL IL298307A patent/IL298307A/en unknown
- 2019-09-05 BR BR112021003962-7A patent/BR112021003962A2/en unknown
- 2019-09-05 AU AU2019335006A patent/AU2019335006B2/en active Active
- 2019-09-05 CA CA3111332A patent/CA3111332A1/en active Pending
- 2019-09-05 SG SG11202102104SA patent/SG11202102104SA/en unknown
- 2019-09-05 EP EP19195692.9A patent/EP3620174B1/en active Active
- 2019-09-05 US US17/274,016 patent/US20220226401A1/en active Pending
- 2019-09-05 EP EP22151940.8A patent/EP4082568A1/en active Pending
- 2019-09-05 IL IL281177A patent/IL281177B2/en unknown
- 2019-09-05 US US16/561,953 patent/US11590221B2/en active Active
- 2019-09-05 MX MX2021002586A patent/MX2021002586A/en unknown
- 2019-09-05 WO PCT/US2019/049749 patent/WO2020051334A1/en active Application Filing
- 2019-09-05 ES ES19195692T patent/ES2908304T3/en active Active
- 2019-09-05 KR KR1020217009759A patent/KR20210071979A/en unknown
-
2021
- 2021-03-05 PH PH12021550479A patent/PH12021550479A1/en unknown
- 2021-03-29 CO CONC2021/0003931A patent/CO2021003931A2/en unknown
- 2021-04-05 EC ECSENADI202123398A patent/ECSP21023398A/en unknown
-
2023
- 2023-01-04 US US18/149,742 patent/US20230355748A1/en active Pending
-
2024
- 2024-04-03 JP JP2024060499A patent/JP2024105238A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021003931A2 (en) | 2021-04-19 |
| JP2021536463A (en) | 2021-12-27 |
| IL281177B1 (en) | 2023-11-01 |
| WO2020051334A1 (en) | 2020-03-12 |
| ECSP21023398A (en) | 2021-06-30 |
| CA3111332A1 (en) | 2020-03-12 |
| EP3846849A1 (en) | 2021-07-14 |
| US20220226401A1 (en) | 2022-07-21 |
| IL281177A (en) | 2021-04-29 |
| PE20211545A1 (en) | 2021-08-16 |
| EP3620174B1 (en) | 2022-01-19 |
| MX2021002586A (en) | 2021-06-08 |
| BR112021003962A2 (en) | 2021-05-25 |
| ES2908304T3 (en) | 2022-04-28 |
| IL298307A (en) | 2023-01-01 |
| EP3620174A1 (en) | 2020-03-11 |
| CN112912106A (en) | 2021-06-04 |
| PH12021550479A1 (en) | 2021-10-25 |
| IL281177B2 (en) | 2024-03-01 |
| DK3620174T3 (en) | 2022-03-14 |
| AU2019335006B2 (en) | 2024-07-04 |
| US11590221B2 (en) | 2023-02-28 |
| US20200230230A1 (en) | 2020-07-23 |
| AU2019335006A1 (en) | 2021-05-06 |
| KR20210071979A (en) | 2021-06-16 |
| EP4082568A1 (en) | 2022-11-02 |
| JP2024105238A (en) | 2024-08-06 |
| US20230355748A1 (en) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281177A (en) | Dengue vaccine unit dose and administration thereof | |
| CA186677S (en) | Drug delivery device | |
| GB201704211D0 (en) | Ophthalmic delivery device and ophthalmic drug compositions | |
| EP3354306A4 (en) | Drug administering device and drug administering unit | |
| IL268385B (en) | Drug delivery devices and methods for drug delivery | |
| EP3846884C0 (en) | Medicament delivery device and methods | |
| SG11202106928PA (en) | Medicine administering device and medicine administering system | |
| GB201701935D0 (en) | Medicament delivery devices | |
| IL266094A (en) | Sterile sealed heterogenous medicament delivery device | |
| IL279127A (en) | Delivery devices for administering drugs | |
| GB201712184D0 (en) | Medicament delivery device | |
| IL291196A (en) | Drug dosage determination devices and methods | |
| GB201619561D0 (en) | Medicament delivery device and system | |
| GB2616568B (en) | Medicament delivery device | |
| GB2602574B (en) | Medicament delivery device | |
| EP3733221C0 (en) | Implantable drug delivery device | |
| PT3664800T (en) | Therapeutic formulations and uses thereof | |
| GB201801898D0 (en) | Medicament delivery devices | |
| GB201801896D0 (en) | Medicament delivery devices | |
| GB201713899D0 (en) | Multi-dose medicament delivery device | |
| GB2583896B (en) | Drug delivery and administration device | |
| GB201813904D0 (en) | An influenza prevention and treatment drug preparation device | |
| GB2580562B (en) | Medicament delivery device | |
| GB201802743D0 (en) | Medicament and use thereof | |
| IL268309B (en) | Implantable device with enhanced drug delivery area |